Tonix Pharma ( (TNXP) ) just unveiled an announcement.
On September 6, 2024, a company showcased their latest vaccine platform data at a symposium, focusing on the TNX-801 vaccine candidate aimed at preventing mpox. The vaccine has demonstrated high attenuation compared to older vaccines and improved safety in immunocompromised animals, with no blood or tissue spread even at high doses. This innovation could have significant implications for future outbreaks and the company’s market position, though they caution that these forward-looking statements involve risks and uncertainties.
See more insights into TNXP stock on TipRanks’ Stock Analysis page.
